CN108113982B - 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 - Google Patents
取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 Download PDFInfo
- Publication number
- CN108113982B CN108113982B CN201711268344.0A CN201711268344A CN108113982B CN 108113982 B CN108113982 B CN 108113982B CN 201711268344 A CN201711268344 A CN 201711268344A CN 108113982 B CN108113982 B CN 108113982B
- Authority
- CN
- China
- Prior art keywords
- monoamine oxidase
- substituted aromatic
- aromatic amide
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 aromatic amide compounds Chemical class 0.000 title claims abstract description 16
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 title claims abstract description 11
- 239000002899 monoamine oxidase inhibitor Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 20
- 229940053482 antidepressant drug mao a inhibitors Drugs 0.000 claims description 2
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 28
- 108010062431 Monoamine oxidase Proteins 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- WZTJFRVXSHGGEF-UHFFFAOYSA-N 1-chloro-4-(2-phenylethyl)benzene Chemical compound C1=CC(Cl)=CC=C1CCC1=CC=CC=C1 WZTJFRVXSHGGEF-UHFFFAOYSA-N 0.000 description 1
- KEJXHTBYIHTFHA-UHFFFAOYSA-N 7-(3-aminopropoxy)-4-methylchromen-2-one Chemical compound C1=C(OCCCN)C=CC2=C1OC(=O)C=C2C KEJXHTBYIHTFHA-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- SAHUGTLKYCOGFB-UHFFFAOYSA-N piperidin-1-yl-[3-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCCCC2)=C1 SAHUGTLKYCOGFB-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用，所述取代芳酰胺类化合物的结构式如式(I‑1)、(I‑7)或(II‑2)所示：
Description
(一)技术领域
本发明涉及取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用。
(二)背景技术
帕金森病(Parkinson’s disease，PD)是一种常见的神经系统变性疾病和运动障碍慢性疾病，常合并有行为或心理的异常，严重影响患者的生活质量(Dauer W，Przedborski S，Parkinson'sdisease:mechanisms and models.Neuron,2003,39(6):889-909.)。每年4月11日是世界卫生组织确定的世界帕金森病日。当前全球有一半以上的帕金森病人在中国，总数超过200万。我国60岁以上的老年人发病率超过1％，但从近年来发病及就诊的患者年龄来看，正呈现低龄化趋势，“青少年型帕金森病”患者占总人数的10％。抑郁症是一种常见的精神病理状态或综合征，其程度可以从轻度的忧伤到重度的绝望、自杀企图等；其引发的主要原因是中枢去甲肾上腺素和5-羟色胺、多巴胺这些特定的神经递质的水平过低及其受体功能低下。它有发病率高和发病年龄广泛的特点，给人们的工作和生活造成了严重的影响。
单胺氧化酶抑制剂是临床上用于治疗多种疾病的一类药物：其中单胺氧化酶A抑制剂主要用于治疗抑郁症，而单胺氧化酶B抑制剂主要用于治疗帕金森病。单胺氧化酶抑制剂可分为可逆性和不可逆性抑制剂，像早期的不可逆性抑制剂闷可乐、苯乙肼这些药物有很强的副作用。因此，寻求抑制性强、选择性高、毒副作用小的单胺氧化酶抑制剂已成为改领域的热点问题。
单胺氧化酶(Monoamine oxidase,MAO,EC1.4.3.4)全名为单胺氧化还原酶，它在大脑和周围神经组织中催化一些生物体产生的胺，氧化脱氨产生过氧化氢。根据底物选择性和对抑制剂的灵敏度，单胺氧化酶被分为A和B两种。单胺氧化酶A对底物血清素(52HT)、去甲肾上腺素(NE)、多巴胺(DA)具有高亲和性；而单胺氧化酶B则对苯乙基胺(PEA)和苯甲胺具有高亲和性。研究表明它与人的多种行为和疾病有关，如抑郁症、帕金森氏综合症等(Brunner H G,Nelen M,Breakefield X O，et al.Abnormal behavior associated witha point mutation in the structural gene for monoamine oxidase A.Science,1993,262(5133):578-580)。
本发明设计与合成了一类取代芳酰胺类化合物，经生物活性检测发现它们具有极好的单胺氧化酶抑制活性，是一类高活性的单胺氧化酶抑制剂。
(三)发明内容
本发明的目的是提供取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用。
本发明采用如下技术方案：
本发明提供了取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用，所述取代芳酰胺类化合物的结构式如式(I-1)、(I-7)或(II-2)所示：
上述化合物中，化合物(I-1)、(I-7)对单胺氧化酶A有较强抑制活性；化合物(I-1)、(I-7)、(II-2)对单胺氧化酶B有较强抑制活性。
本发明所述的取代芳酰胺类化合物均可按照现有文献公开的方法进行制备。
与现有技术相比，本发明的有益效果在于本发明提供的取代芳酰胺类化合物都具有良好的的单胺氧化酶抑制活性。
(四)具体实施方式
下面结合具体实施例对本发明进行进一步描述，但本发明的保护范围并不仅限于此：
本发明实施例中使用的Ru/C购自沈阳展宇科技开发有限公司，型号为REASB，其中Ru含量为5％(g/g)。
实施例1 N-(3,4-二甲氧基苯乙基)-3-(三氟甲基)苯甲酰胺(Ⅰ-1)的合成
将0.93g(5mmol)化合物(IX-1)、0.91g(5mmol)化合物物(X-1)、Ru/C催化剂(0.05g)，和20mL四氢呋喃(THF)加入到反应瓶中，30℃下敞口搅拌反应20小时，TLC监测反应，待反应完全，将反应液过滤，滤渣用二氯甲烷洗涤两次，合并滤液，用二氯甲烷和水体系萃取，收集有机相，干燥，浓缩，层析柱分离，制得N-(3,4-二甲氧基苯乙基)-3-(三氟甲基)苯甲酰胺(I-1)。
化合物(I-1)的表征数据如下：
1H NMR(600MHz,CDCl3):δ7.98(s,1H),7.88(d,J＝7.8Hz,1H),7.74(d,J＝7.8Hz,1H),7.55-7.52(t,J＝7.8Hz,1H),6.83(d,J＝7.8Hz,1H),6.77-6.74(m,2H),6.57(s,1H),3.87(d,6H),3.68(t,J＝6.6Hz,2H),2.92-2.90(t,J＝6.6Hz,2H)；GC-MS(EI):m/z 353[M+].
实施例2 N-(4-氯苯乙基苯)-3-(三氟甲基)甲酰胺(I-7)的合成
实验方法同实施例1，这里就不再赘述。化合物(I-7)的表征数据如下：
1H NMR(600MHz,CDCl3)δ8.11(s,1H),7.98(s,1H),7.88(d,J＝7.8Hz,1H),7.74(d,J＝7.8Hz,1H),7.55-7.52(t,1H),7.29-7.27(m,2H),7.16(d,J＝7.8Hz,2H),6.57(s,1H),3.68-3.66(m,2H),2.92-2.90(t,J＝7.2Hz,2H)；GC-MS(EI):m/z 327[M+].
实施例3哌啶-1-基(3-(三氟甲基)苯基)甲酮(II-2)的合成
实验方法同实施例1，这里就不再赘述。化合物(II-2)的表征数据如下：
1H NMR(600MHz,CDCl3)δ7.58(d,2H),7.49(d,J＝7.2Hz,1H),7.46(d,J＝7.8Hz,1H),3.64(s,2H),3.23(s,2H),1.61(s,4H),1.44(s,2H)；GC-MS(EI):m/z 257[M+].
实施例4所合成化合物单胺氧化酶抑制活性的测试
(1)样品配制
将实施例1～3制备的化合物(Ⅰ-1)、(Ⅰ-7)、(Ⅱ-2)溶于二甲基亚砜(DMSO)中，分别配成0.5，1，10，25，50，100，200，400，800，1600μmol/L浓度梯度的样品液，记为样品1～3。
(2)所合成化合物对单胺氧化酶-A抑制活性测试检测方法
分别向3份装有371μL硼酸缓冲液(pH＝8.4)的EP管中加入15μL单胺氧化酶-A和10μL步骤(1)配制的样品1～3混合，再将混合物在38℃水浴中反应3h，然后分别向上述3份EP管中加入2μL下式所示的探针7-(3-氨基丙氧基)-4-甲基香豆素(20mmol/ml)和2μL的牛血清蛋白(BSA，20mg/mL)，并各个EP管置于38℃水浴中继续反应1.5h。与其同时需检测未加抑制剂的MAO-A的酶活，即向装有381μL硼酸缓冲液(pH＝8.4)的EP管中加入15μL单胺氧化酶-A(MAO-A)，在38℃水浴中反应3h，再加入2μL探针(20mmol/ml)和2μL的BSA同样也在38℃水浴中反应1.5h。
最后在每个EP管(微量离心管)中取出100μL加入96孔板中并用全功能荧光分光光度计(λex/λem＝365/460nm)(spectraMax M,美国分子仪器公司)检测样品。根据所测的荧光值计算样品1～3的IC50，化合物(Ⅰ-1)、(Ⅰ-7)、(Ⅱ-2)对单胺氧化酶-A活性抑制测试结果见表1。
化合物的抑制效果用半数抑制浓度(IC50)来表示。IC50是指“反应”被抑制一半时抑制剂的浓度，化合物抑制能力越强，该数值越低。
IC50可以用以下方法计算：
1)检测并计算只加酶与探针缓冲液的平均荧光强度(FM)；
2)计算含有不同浓度梯度抑制剂的各组分酶的荧光强度(要扣除背景值)；
3)根据不同浓度梯度抑制剂的各组分酶的荧光强度做抑制剂的浓度(C)与荧光强度(F)
之间关系的直线回归，建立得到方程：F＝aC+b(通过回归直线确定方程系数a和截踞b)；
4)根据方程，求F＝1/2FM下的对应的抑制剂浓度，即可求出抑制率为50％时的抑制剂浓度，即为IC50
(3)所合成化合物对单胺氧化酶-B抑制活性测试
将单胺氧化酶A换成单胺氧化酶B，样品配制及操作同步骤(2)，结果如表1所示。
表1实施例1～3制备的化合物(Ⅰ-1)、(Ⅰ-7)、(Ⅱ-2)对单胺氧化酶A和B的抑制活性[a]
| 化合物 | IC<sub>50</sub>(MAO-A)(μM) | IC<sub>50</sub>(MAO-B)(μM) | SI<sup>[b]</sup> |
| (I-1) | 236.5647 | 161.8118 | 1.4620 |
| (I-7) | 296.6892 | 153.8597 | 1.9283 |
| (II-2) | 4020.7860 | 136.5278 | 29.4503 |
[a]抑制剂的活性用IC50表示，每个样品做5个浓度梯度，每组3个平行；[b]对酶的选择性用SI表示，SI:selectivity index＝IC50(MAO-A)/IC50(MAO-B)；[c]ND表示活性很小。
从表1可以看出，化合物(I-1)、(I-7)对单胺氧化酶A有较强抑制活性；化合物(I-1)、(I-7)、(II-2)对单胺氧化酶B有较强抑制活性。
Claims (3)
1.取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用，其特征在于：所述取代芳酰胺类化合物的结构式如式(I-1)、(I-7)或(II-2)所示：
2.如权利要求1所述的应用，其特征在于：化合物(I-1)、(I-7)在制备单胺氧化酶A抑制剂中的应用。
3.如权利要求1所述的应用，其特征在于：化合物(I-1)、(I-7)、(II-2)在制备单胺氧化酶B抑制剂中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711268344.0A CN108113982B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711268344.0A CN108113982B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201510954689.6A CN105534964B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺或含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510954689.6A Division CN105534964B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺或含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108113982A CN108113982A (zh) | 2018-06-05 |
| CN108113982B true CN108113982B (zh) | 2020-04-17 |
Family
ID=55814895
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711268344.0A Active CN108113982B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201510954689.6A Active CN105534964B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺或含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711270076.6A Active CN107982251B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711268288.0A Active CN107898786B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711268284.2A Active CN107875152B (zh) | 2015-12-17 | 2015-12-17 | 含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510954689.6A Active CN105534964B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺或含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711270076.6A Active CN107982251B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711268288.0A Active CN107898786B (zh) | 2015-12-17 | 2015-12-17 | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 |
| CN201711268284.2A Active CN107875152B (zh) | 2015-12-17 | 2015-12-17 | 含氮杂环类化合物在制备单胺氧化酶抑制剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN108113982B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642766B (zh) * | 2019-08-30 | 2021-05-11 | 浙江工业大学 | 一种单胺氧化酶a抑制剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982170A (zh) * | 2010-10-12 | 2011-03-02 | 浙江工业大学 | 酰胺类化合物在制备单胺氧化酶抑制剂中的应用及化合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
-
2015
- 2015-12-17 CN CN201711268344.0A patent/CN108113982B/zh active Active
- 2015-12-17 CN CN201510954689.6A patent/CN105534964B/zh active Active
- 2015-12-17 CN CN201711270076.6A patent/CN107982251B/zh active Active
- 2015-12-17 CN CN201711268288.0A patent/CN107898786B/zh active Active
- 2015-12-17 CN CN201711268284.2A patent/CN107875152B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982170A (zh) * | 2010-10-12 | 2011-03-02 | 浙江工业大学 | 酰胺类化合物在制备单胺氧化酶抑制剂中的应用及化合物 |
Non-Patent Citations (2)
| Title |
|---|
| Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B;Giuseppe La Regina等;《Bioorganic & Medicinal Chemistry》;20081231;第16卷;9729-9740 * |
| 单胺氧化酶抑制剂的研究进展;宋明贵等;《浙江化工》;20111231;第42卷(第4期);12-18 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107982251B (zh) | 2020-08-21 |
| CN105534964B (zh) | 2018-05-22 |
| CN107898786B (zh) | 2020-08-21 |
| CN107898786A (zh) | 2018-04-13 |
| CN105534964A (zh) | 2016-05-04 |
| CN107982251A (zh) | 2018-05-04 |
| CN107875152B (zh) | 2020-03-24 |
| CN108113982A (zh) | 2018-06-05 |
| CN107875152A (zh) | 2018-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chimenti et al. | Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors | |
| Huang et al. | Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl) indazoles as novel anti-angiogenic agents | |
| Tok et al. | Synthesis of new hydrazone derivatives and evaluation of their monoamine oxidase inhibitory activity | |
| Chimenti et al. | Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3, 5-diphenyl-4, 5-dihydro-(1H)-pyrazole derivatives | |
| Payrits et al. | A novel 3-(4, 5-diphenyl-1, 3-oxazol-2-yl) propanal oxime compound is a potent Transient Receptor Potential Ankyrin 1 and Vanilloid 1 (TRPA1 and V1) receptor antagonist | |
| EP1807390A2 (en) | Arylalkyl ureas as cb1 antagonists | |
| Khattab et al. | Synthesis and evaluation of quinazoline amino acid derivatives as mono amine oxidase (MAO) inhibitors | |
| Sinha et al. | Synthesis of isonicotinic acid N′-arylidene-N-[2-oxo-2-(4-aryl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents | |
| CN108558831A (zh) | 取代吡咯-4-烷基胺类化合物及其用途 | |
| Heinrich et al. | Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity | |
| Sant’Anna et al. | Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors | |
| Strydom et al. | Inhibition of monoamine oxidase by phthalide analogues | |
| EP2046722B1 (en) | Beta-3 receptor ligands and their use in therapy | |
| Grunewald et al. | Synthesis and biochemical evaluation of 3-fluoromethyl-1, 2, 3, 4-tetrahydroisoquinolines as selective inhibitors of phenylethanolamine N-methyltransferase versus the α2-adrenoceptor | |
| CN108113982B (zh) | 取代芳酰胺类化合物在制备单胺氧化酶抑制剂中的应用 | |
| Jia et al. | Rapid synthesis of flavone‐based monoamine oxidase (MAO) inhibitors targeting two active sites using click chemistry | |
| Zhang et al. | Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs | |
| HU225111B1 (en) | Aminomethylindans, -benzofuranes and-benzothiophenes and pharmaceutical compositions containing them | |
| La Regina et al. | Synthesis, structure–activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B | |
| Kobayashi et al. | Identification of N-acyl-N-indanyl-α-phenylglycinamides as selective TRPM8 antagonists designed to mitigate the risk of adverse effects | |
| Tonelli et al. | Exploring the effectiveness of novel benzimidazoles as CB2 ligands: synthesis, biological evaluation, molecular docking studies and ADMET prediction | |
| Gökhan-Kelekçi et al. | Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors | |
| Jia et al. | Design, synthesis and antitumor activity evaluation of novel indole acrylamide derivatives as IMPDH inhibitors | |
| Mbaba et al. | The in Vitro Antiplasmodial and Antiproliferative Activity of New Ferrocene‐Based α‐Aminocresols Targeting Hemozoin Inhibition and DNA Interaction | |
| EP2432766B1 (fr) | Composé anticancéreux et composition pharmaceutique le contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |